Sanctuary Advisors LLC Boosts Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sanctuary Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.8% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 61,514 shares of the medical research company's stock after acquiring an additional 6,470 shares during the period. Sanctuary Advisors LLC's holdings in Thermo Fisher Scientific were worth $38,051,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of TMO. Silver Lake Advisory LLC increased its stake in shares of Thermo Fisher Scientific by 30.1% in the 2nd quarter. Silver Lake Advisory LLC now owns 977 shares of the medical research company's stock valued at $540,000 after purchasing an additional 226 shares in the last quarter. Triad Wealth Partners LLC purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth $43,000. LA Financiere DE L Echiquier grew its position in shares of Thermo Fisher Scientific by 3.4% in the second quarter. LA Financiere DE L Echiquier now owns 111,877 shares of the medical research company's stock valued at $61,868,000 after purchasing an additional 3,667 shares during the period. Benson Investment Management Company Inc. raised its position in shares of Thermo Fisher Scientific by 15.3% during the 2nd quarter. Benson Investment Management Company Inc. now owns 9,104 shares of the medical research company's stock worth $5,035,000 after purchasing an additional 1,209 shares during the last quarter. Finally, Miracle Mile Advisors LLC boosted its holdings in Thermo Fisher Scientific by 5.9% in the 2nd quarter. Miracle Mile Advisors LLC now owns 5,760 shares of the medical research company's stock worth $3,185,000 after buying an additional 320 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares of the company's stock, valued at $67,175,513.68. This trade represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares of the company's stock, valued at approximately $9,333,946.08. This represents a 1.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,150 shares of company stock valued at $25,954,465 over the last quarter. Corporate insiders own 0.34% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on TMO shares. Bernstein Bank increased their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a "market perform" rating in a research report on Tuesday, October 22nd. TD Cowen upped their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Bank of America increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a "buy" rating in a research report on Monday, September 16th. Evercore ISI lowered their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Finally, JPMorgan Chase & Co. boosted their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an "overweight" rating in a research report on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $649.33.

Thermo Fisher Scientific Price Performance

TMO traded down $9.50 on Thursday, hitting $524.86. 2,539,146 shares of the company were exchanged, compared to its average volume of 1,539,860. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The firm has a market capitalization of $200.76 billion, a P/E ratio of 33.50, a price-to-earnings-growth ratio of 3.56 and a beta of 0.77. The business's fifty day moving average is $553.35 and its 200 day moving average is $574.46.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the business posted $5.69 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's payout ratio is currently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.